Sumatriptan
Jun 22, 2011 at 09:23 | Source: Moneycontrol.com
Jul 22, 2010 at 18:24 | Source: CNBC-TV18
Jun 15, 2010 at 08:14 | Source: Reuters
Jul 10, 2009 at 19:14 | Source: Moneycontrol.com
May 21, 2009 at 16:19 | Source: Moneycontrol.com
Feb 18, 2009 at 10:08 | Source: Moneycontrol.com
Related News »
(HealthDay) -- Treatment with sumatriptan and naproxen sodium (suma/nap) is well tolerated and effective in reducing migraine pain in adolescents, according to a study published online May 14 in Pediatrics. Frederick J. Derosier, D.O., from ...
May 15, 2012 at 08:37 | Source: medicalxpress.com
Objectives.— The primary objective was to compare the efficacy of a sumatriptan and naproxen combination medication (SumaRT/Nap—85 mg sumatriptan and 500 mg naproxen sodium), a butalbital-containing combination medication (BCM—50 mg ...
May 18, 2012 at 10:07 | Source: Medscape News
The combination of sumatriptan and naproxen sodium safely and effectively relieves acute adolescent migraine pain and its associated symptoms compared with placebo, according to the results of a new randomized trial. Billed as the first large ...
May 17, 2012 at 02:30 | Source: ModernMedicine
U.S. researchers tested three doses of sumatriptan and naproxen sodium in teens with migraines and found that all doses were well tolerated and effective in relieving pain two hours after dosing. The study in Pediatrics found no significant difference in ...
May 15, 2012 at 15:32 | Source: SmartBrief
Because the combination of Imitrex (sumatriptan) and naproxen sodium (Aleve and other brand names) isn't approved for use by the U.S. Food and Drug Administration for this age group, doctors must prescribe it "off label" to adolescents.
May 15, 2012 at 20:04 | Source: US News and World Report
No triptans are approved in those under 12, and only sumatriptan nasal spray (European Union) and almotriptan tablets (USA) are approved for those aged 12–17. Appropriate dose selection based on body weight may be a factor in establishing ...
May 25, 2012 at 10:06 | Source: Medscape News
MT 400 is Pozen's proprietary combination of sumatriptan and naproxen sodium, the first multiple mechanism triptan therapy for the treatment of migraine. Q: What do investors need to know about this news? How does this deal change your financial forecast ...
May 14, 2012 at 14:22 | Source: Seekingalpha.com
MT 400 is POZEN’s proprietary combination of sumatriptan and naproxen sodium, the first multiple mechanism triptan therapy for the treatment of migraine. POZEN previously licensed rights of the same dosage strength of MT 400 to Cilag GmbH International ...
May 8, 2012 at 11:30 | Source: StreetInsider.com
In January, the USPTO issued a notice of allowance for U.S. Patent application 12/142,604 entitled "Pharmacokinetics of Iontophoretic Sumatriptan Administration." This application relates to methods of treating a migraine by administering sumatriptan using ...
May 10, 2012 at 11:49 | Source: Stockhouse